General Information of Drug (ID: DM1RPL4)

Drug Name
PMID29671355-Compound-67 Drug Info
Cross-matching ID
PubChem CID
60201048
TTD Drug ID
DM1RPL4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [2]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
PMID29671355-Compound-8 DM7YQJK N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
TMP269 DMSMQE7 Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Citarinostat DMQLODU Multiple myeloma 2A83 Phase 1 [4]
KA2507 DMW0H9Y Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NBM-BMX DM5OWXA Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [2]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
PMID29671355-Compound-68b DMLGBR6 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [6]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [7]
Panobinostat DM58WKG Chronic graft versus host disease Approved [6]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [8]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [9]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [10]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [11]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [12]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [6]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
TMP269 DMSMQE7 Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [1]
Histone deacetylase 2 (HDAC2) TTSHTOI HDAC2_HUMAN Inhibitor [1]
Histone deacetylase 3 (HDAC3) TT4YWTO HDAC3_HUMAN Inhibitor [1]
Histone deacetylase 4 (HDAC4) TTTQGH8 HDAC4_HUMAN Inhibitor [1]
Histone deacetylase 5 (HDAC5) TTUELN5 HDAC5_HUMAN Inhibitor [1]
Histone deacetylase 6 (HDAC6) TT5ZKDI HDAC6_HUMAN Inhibitor [1]
Histone deacetylase 7 (HDAC7) TTMUEK1 HDAC7_HUMAN Inhibitor [1]
Histone deacetylase 8 (HDAC8) TTT6LFV HDAC8_HUMAN Inhibitor [1]

References

1 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
2 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
3 Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
6 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
10 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
11 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
12 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
13 2011 Pipeline of 4SC AG.